Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Hellyer, Thomas PMcAuley, Daniel F
Walsh, Timothy S
Anderson, Niall
Conway Morris, Andrew
Singh, Suveer
Dark, Paul
Roy, Alistair I
Perkins, Gavin D
McMullan, Ronan
Emerson, Lydia M
Blackwood, Bronagh
Wright, Stephen E
Kefala, Kallirroi
O'Kane, Cecilia M
Baudouin, Simon V
Paterson, Ross L
Rostron, Anthony J
Agus, Ashley
Bannard-Smith, Jonathan
Robin, Nicole M
Welters, Ingeborg D
Bassford, Christopher
Yates, Bryan
Spencer, Craig
Laha, Shondipon K
Hulme, Jonathan
Bonner, Stephen
Linnett, Vanessa
Sonksen, Julian
Van Den Broeck, Tina
Boschman, Gert
Keenan, Dw James
Scott, Jonathan
Allen, A Joy
Phair, Glenn
Parker, Jennie
Bowett, Susan A
Simpson, A John
Affiliation
Newcastle University; Queen's University Belfast; The Royal Hospitals, Belfast; University of Edinburgh; Royal Infirmary of Edinburgh; University of Cambridge; Addenbrooke's Hospital; Imperial College London; University of Manchester; City Hospitals Sunderland NHS Foundation Trust; University of Warwick; University Hospitals Birmingham NHS Foundation Trust; Newcastle upon Tyne Hospitals NHS Foundation Trust; Western General Hospital; Manchester University NHS Foundation Trust; Countess of Chester NHS Foundation Trust; University of Liverpool; University Hospitals Coventry and Warwickshire NHS Trust; Northumbria Specialist Emergency Care Hospital; Lancashire Teaching Hospitals NHS Foundation Trust; Sandwell and West Birmingham Hospitals NHS Trust; South Tees Hospitals NHS Foundation Trust; Gateshead NHS Foundation Trust; Dudley Group NHS Foundation Trust; Becton Dickinson Biosciences EuropePublication date
2019-12-03
Metadata
Show full item recordAbstract
Background: Ventilator-associated pneumonia is the most common intensive care unit (ICU)-acquired infection, yet accurate diagnosis remains difficult, leading to overuse of antibiotics. Low concentrations of IL-1β and IL-8 in bronchoalveolar lavage fluid have been validated as effective markers for exclusion of ventilator-associated pneumonia. The VAPrapid2 trial aimed to determine whether measurement of bronchoalveolar lavage fluid IL-1β and IL-8 could effectively and safely improve antibiotic stewardship in patients with clinically suspected ventilator-associated pneumonia. Methods: VAPrapid2 was a multicentre, randomised controlled trial in patients admitted to 24 ICUs from 17 National Health Service hospital trusts across England, Scotland, and Northern Ireland. Patients were screened for eligibility and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected ventilator-associated pneumonia. Patients were randomly assigned (1:1) to biomarker-guided recommendation on antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service hosted by Newcastle Clinical Trials Unit. Patients were randomised using randomly permuted blocks of size four and six and stratified by site, with allocation concealment. Clinicians were masked to patient assignment for an initial period until biomarker results were reported. Bronchoalveolar lavage was done in all patients, with concentrations of IL-1β and IL-8 rapidly determined in bronchoalveolar lavage fluid from patients randomised to the biomarker-based antibiotic recommendation group. If concentrations were below a previously validated cutoff, clinicians were advised that ventilator-associated pneumonia was unlikely and to consider discontinuing antibiotics. Patients in the routine use of antibiotics group received antibiotics according to usual practice at sites. Microbiology was done on bronchoalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at least 104 colony forming units per mL of bronchoalveolar lavage fluid. The primary outcome was the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage. Data were analysed on an intention-to-treat basis, with an additional per-protocol analysis that excluded patients randomly assigned to the intervention group who defaulted to routine use of antibiotics because of failure to return an adequate biomarker result. An embedded process evaluation assessed factors influencing trial adoption, recruitment, and decision making. This study is registered with ISRCTN, ISRCTN65937227, and ClinicalTrials.gov, NCT01972425. Findings: Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study. 146 patients were ineligible, leaving 214 who were recruited to the study. Four patients were excluded before randomisation, meaning that 210 patients were randomly assigned to biomarker-guided recommendation on antibiotics (n=104) or routine use of antibiotics (n=106). One patient in the biomarker-guided recommendation group was withdrawn by the clinical team before bronchoscopy and so was excluded from the intention-to-treat analysis. We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58). Bronchoalveolar lavage was associated with a small and transient increase in oxygen requirements. Established prescribing practices, reluctance for bronchoalveolar lavage, and dependence on a chain of trial-related procedures emerged as factors that impaired trial processes. Interpretation: Antibiotic use remains high in patients with suspected ventilator-associated pneumonia. Antibiotic stewardship was not improved by a rapid, highly sensitive rule-out test. Prescribing culture, rather than poor test performance, might explain this absence of effect.Citation
Hellyer TP, McAuley DF, Walsh TS, Anderson N, Conway Morris A, Singh S, Dark P, Roy AI, Perkins GD, McMullan R, Emerson LM, Blackwood B, Wright SE, Kefala K, O'Kane CM, Baudouin SV, Paterson RL, Rostron AJ, Agus A, Bannard-Smith J, Robin NM, Welters ID, Bassford C, Yates B, Spencer C, Laha SK, Hulme J, Bonner S, Linnett V, Sonksen J, Van Den Broeck T, Boschman G, Keenan DJ, Scott J, Allen AJ, Phair G, Parker J, Bowett SA, Simpson AJ. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. Lancet Respir Med. 2020 Feb;8(2):182-191. doi: 10.1016/S2213-2600(19)30367-4. Epub 2019 Dec 3.Type
ArticleAdditional Links
https://www.thelancet.com/journals/lanres/homePMID
31810865Journal
The Lancet Respiratory MedicinePublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/S2213-2600(19)30367-4